Drugs / Zeushield Cytotoxic T Lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03060343 | Nov 2016 → Nov 2018 | non-small cell lung carcinoma | Yu Fenglei | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zeushield Cytotoxic T Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03060343 ↗ |
| Known as | Z-CTLs | “Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC)” NCT03060343 ↗ |
| Modality | Cell therapy | “patients have their T-cells (a type of white blood cell) collected and modified in the laboratory, before they are given back to the patient” NCT03060343 ↗ |